INTRODUCTION {#s1}
============

Inflammatory reaction play crucial role in shaping tumor development in many aspects, ranging from tumor initiation to tumor metastasis \[[@R1]\]. Inflammatory related peripheral cells (neutrophils, lymphocytes and platelets) derived from the peripheral blood were significantly associated with tumor progression in various tumors \[[@R2]--[@R4]\]. Moreover, infiammatory indexes (II) obtained with different combinations of these factors, such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), have been investigated as useful prognostic factors in various malignant solid tumors \[[@R5]--[@R7]\]. A novel inflammatory index, the systemic immune inflammation index (SII), defined as follows: SII = P\*N/L, where P, N and L were the peripheral platelet, neutrophil and lymphocyte counts \[[@R8]\], was recently investigated as a prognostic marker in various malignancies. Geng et al. \[[@R9]\] suggested that SII was superior to the other systemic inflammation index such as PLR and NLR, and served as a more objective marker that reflects the balance between host inflammatory and immune response status.

The goal of the present study was to conduct a meta-analysis to investigate the association between peripheral blood SII in solid tumors and clinical outcome. Our hypothesis was that elevated SII correlates with worse OS and may thus serve as a readily available and inexpensive prognostic marker in clinical practice.

MATERIALS AND METHODS {#s2}
=====================

Study identification and selection {#s2_1}
----------------------------------

Studies regarding the association between SII and clinical outcome in solid tumors published before February 12, 2017 were included through PubMed, Embase and Cochrane library searching by using the following terms and key words: (systemic immune inflammation index OR SII) AND cancer. The criteria used for the study selection were as followed: 1) studies were concerned about the prognostic impact of SII; 2) A hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS) was available; 3) there were no overlapping data. Two of the authors (Jiehui Zhong, Danhui Huang) evaluated the eligibility of all studies independently collected from the databases based on the selection criteria. The Newcastle-Ottawa Scale (NOS) was used to assess study quality, which consists of three parameters of quality: selection (0--4 points), comparability (0--2 points), and outcome assessment (0--3 points) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Studies with the scores ≥ 6 were assigned as high-quality studies.

Data extraction {#s2_2}
---------------

Information was carefully extracted from all the eligible studies independently by three investigators according to the selection criteria listed above. The following data were collected: first author's name, publication year, country, type of publication (abstract, full text), number of patients included in analysis, disease site, disease stage (metastatic, nonmetastatic, mixed \[metastatic and nonmetastatic\]), collection of data (prospective, retrospective), cutoff defining high SII used for peripheral blood SII, and hazard ratios and 95% confidence interval (CI) for OS, CSS, or RFS as applicable. Hazard ratios based on multivariable analyses other than univariate analyses were extracted prior. We did not require a minimum number of patients to be included in our meta-analysis.

Statistical analysis {#s2_3}
--------------------

Meta-analysis was conducted using RevMan 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). Estimation of hazard ratios was pooled using the random-effect model or the fixed-effect model. Heterogeneity assumption was tested by a chi-square-based *Q* test. Proportion of the total variation across studies due to heterogeneity was checked by *I*-square statistics \[[@R10]\]. A *P*-value of \> 0.05 for the *Q*-test indicated a lack of heterogeneity among studies, so that the pooled HR estimate of each study was calculated by the fixed-effect model \[[@R11]\]. Otherwise, the random-effect model was used \[[@R12]\]. Subgroup analyses were conducted according to disease site (i.e., hepatocellular carcinoma or urinary cancers), disease stage (metastatic/mixed or nonmetastatic), cutoffs for SII (SII ≥ 572 or SII \< 572), data collection (prospective or retrospective), analysis of HR (multivariable or univariable) and article type (abstract or full paper). Differences between the subgroups were assessed using methods described by Deeks et al. \[[@R13]\]. The effect of SII cutoff on the hazard ratio for OS was evaluated by meta-regression analysis. Publication bias is the tendency on the parts of investigators, reviewers, and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings \[[@R14]\]. An estimate of potential publication bias was carried out by the funnel plot, in which the standard error of log (HR) of each study was plotted against its log (HR). Funnel plot asymmetry was further assessed by the method of Egger's linear regression test (*P \<* 0.05 was considered a significant publication bias) \[[@R15]\].

RESULTS {#s3}
=======

Extraction process and study characteristics {#s3_1}
--------------------------------------------

The selection procedure was listed in Figure [1](#F1){ref-type="fig"}. Totally, 837 articles of interest were found after preliminary search, and 40 of them have relevant content on the association between SII and clinical outcome in solid tumors. Among them, 25 studies met the exclusion criterion due to duplication or lack of available data. Hence, 15 publications \[[@R8], [@R9], [@R16]--[@R28]\] including 16 studies (4875 patients) were selected. The characteristics of the studies included were shown in Table [1](#T1){ref-type="table"}. Of them, there were 5 hepatocellular carcinoma studies, 2 esophageal squamous cell carcinoma studies, 2 gastric cancer studies, 1 renal cell cancer study, 1 malignant obstructive jaundice study, 1 small cell lung cancer studies, 1 colorectal cancer study, 1 biliary tract cancer study, and 1 metastatic castration-resistant prostate cancer study and 1 acral melanoma study. The quality of all 16 studies ranged from 5 to 7 ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}), indicating that most studies included were high quality.

![Flow diagram of included studies for this meta-analysis](oncotarget-08-75381-g001){#F1}

###### Characteristics of studies included in the meta-analysis

  Author           Study Period   Data collection   Ethnicity   Stage           Disease site   Number   Cut-off   Reported endpoints   Follow-up Median (month)
  ---------------- -------------- ----------------- ----------- --------------- -------------- -------- --------- -------------------- --------------------------
  Hu 2014 1        2005--2006     retrospective     China       mixed           HCC            133      330       OS,                  61.3
  Hu 2014 2        2010--2011     retrospective     China       mixed           HCC            123      330       OS                   28.8
  Lolli 2016 1     2006--2014     retrospective     Italy       metastatic      RCC            335      730       OS, PFS              49
  Lolli 2016 2     2011--2015     retrospective     Italy       metastatic      mCRPC          230      535       OS                   29
  Yang 2015        2009--2015     retrospective     China       mixed           HCC            189      300       OS                   19.8
  Passardic 2016   2007--2012     prospective       Italy       metastatic      CRC            289      730       OS, PFS              36
  Feng 2016        2005--2008     retrospective     China       nonmetastatic   ESCC           298      410       CSS                  NR
  Ha 2016          2004--2009     retrospective     Korea       NR              BTC            158      572.38    OS                   95.3
  Geng 2016        2002--2012     retrospective     China       nonmetastatic   ESCC           916      307       OS                   39
  Jin 2016         2012--2016     retrospective     China       NR              MOJ            33       644       OS                   10
  Hong 2015        2000--2012     retrospective     China       mixed           SCLC           919      1600      OS                   NR
  Liu 2015         2005--2010     retrospective     China       nonmetastatic   GC             455      660       OS                   25
  Gardini 2016     2012--2015     retrospective     Italy       mixed           HCC            56       360       OS, PFS              NR
  Huang 2016       2013--2014     retrospective     China       nonmetastatic   GC             445      572       OS                   54.6
  Gao 2016         2014--2015     retrospective     China       mixed           HCC            183      330       OS                   NR
  Yu 2016          NR             NR                China       NR              AM             113      615       OS                   NR

HCC, hepatocellular carcinoma; MCRPC, metastatic castration-resistant prostate cancer; RCC, renal cell cancer; ESCC, esophageal squamous cell carcinoma; BTC, biliary tract cancer; MOJ, malignant obstructive jaundice; SCLC, small cell lung cancer ; CRC, colorectal cancer; GC, gastric cancer; AM, acral melanoma; OS, overall survival; PFS, progression-free survival; CSS, cancer-specific survival; NR, not reported.

Overall survival {#s3_2}
----------------

15 studies including 4577 patients reported HR for OS. The median cutoff for high SII was 572 (range = 300--1600). SII greater than the cutoff predicted poor OS (HR = 1.55, 95% CI = 1.27--1.88; *P \<* 0.001, Figure [2](#F2){ref-type="fig"}). However, this result is with significant between-study heterogeneity (I-square = 63%, *P \<* 0.001). The influence of SII on OS among cancer subgroups is shown in Table [2](#T2){ref-type="table"}. High SII was associated with significantly worse OS for acral melanoma, hepatocellular carcinoma, urinary cancers, small cell lung cancer, gastrointestinal tract cancers (HRs = 2.54, 2.08, 1.82, 1.38, 1.21, respectively). The influence of SII on OS among different cancer stages is shown in Table [2](#T2){ref-type="table"}. The HRs were 1.65 (95% CI = 1.28--2.13) for metastatic/mixed diseases, 1.48 (95% CI = 1.06--2.05) for nonmetastatic diseases. The subgroups analyses according to cutoffs for SII, data collection, analysis of HR, article type regarding the effect of SII on OS is shown in Table [2](#T2){ref-type="table"}. Meta-regression scatter plot is shown in Figure [3](#F3){ref-type="fig"}. Overall, there was no association between SII cutoff and the HR for OS (*P =* 0.519). Sensitivity analyses investigating the influence by omitting one study at a time and calculating the combined HRs. Any single study did not substantially affect the pooled HRs when deleted from the whole study. Begg's funnel plot and Egger's test were conducted to estimate the publication bias of studies. There was no publication bias because of bias exploration funnel plots demonstrated symmetry (Figure [4](#F4){ref-type="fig"}). Egger's test also validates little publication bias (*P =* 0.123).

![Forest plots of studies evaluating the association between SII and overall survival\
The center of each square represents the HR, the area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI.](oncotarget-08-75381-g002){#F2}

###### Subgroup analyses of overall survival

  **Subgroup**                     **Number of studies**   **HR (95% CI)**     ***P***    ***P~h~***   ***P* for subgroup difference**
  -------------------------------- ----------------------- ------------------- ---------- ------------ ---------------------------------
  Disease site                                                                                         0.001
  Gastrointestinal tract cancers   4                       1.21 (1.03--1.41)   0.02       0.09         
  Urinary cancers                  2                       1.82 (1.43--2.32)   \< 0.001   0.93         
  Hepatocellular carcinoma         5                       2.08 (1.52--2.85)   \< 0.001   0.15         
  Small cell lung cancer           1                       1.38 (1.02--1.85)   0.03       \-           
  Acral melanoma                   1                       2.54 (1.50--4.31)   \< 0.001   \-           
  Other                            2                       1.84 (0.35--9.63)   0.47       0.04         
  Disease stage                                                                                        0.60
  Metastatic/mixed                 9                       1.65 (1.28--2.13)   0.0001     0.01         
  Nonmetastatic                    4                       1.48 (1.06--2.05)   0.02       0.02         
  Cutoffs for SII                                                                                      0.31
  ≥ 572                            8                       1.42 (1.08--1.87)   0.01       0.002        
  \< 572                           7                       1.76 (1.29--2.41)   \< 0.001   0.02         
  Analysis of HR                                                                                       0.10
  Multivariable                    14                      1.59 (1.31--1.93)   \< 0.001   \< 0.001     
  Univariable                      1                       0.75 (0.32--1.78)   0.52       \-           
  Data collection                                                                                      0.02
  Prospective                      1                       0.84 (0.53--1.33)   0.46       \-           
  Retrospective                    13                      1.56 (1.28--1.89)   \< 0.001   0.005        
  Article type                                                                                         0.06
  Abstract                         1                       2.54 (1.50--4.31)   \< 0.001   \-           
  Full paper                       14                      1.49 (1.23--1.81)   \< 0.001   0.002        

The subgroup "gastrointestinal tract cancers" includes 1 esophageal squamous cell carcinoma studies, 1 colorectal cancer study and 2 gastric cancer studies; The subgroup "urinary cancers" includes 1 renal cell cancer study and 1 metastatic castration-resistant prostate cancer study; The subgroup "other" includes 1 malignant obstructive jaundice study and 1 biliary tract cancer study. *P*~*h*~, *P*-values for heterogeneity from *Q* test.

![Univariate meta-regression exploring the association of the cutoff used to define SII and the hazard ratio for overall survival](oncotarget-08-75381-g003){#F3}

![Funnel plots of hazard ratio for overall survival for high SII (horizontal axis) and the standard error (SE) for the hazard ratio (vertical axis)\
Each study is represented by one circle. The vertical line represents the pooled effect estimate.](oncotarget-08-75381-g004){#F4}

Progression-free survival {#s3_3}
-------------------------

Three studies including 680 patients reported HRs for PFS. Overall, SII over the cutoff was not associated with a hazard ratio for worse PFS outcome. The HR for PFS was 1.31 (95% CI = 0.76--2.27, *P =* 0.33, Table [3](#T3){ref-type="table"}).

###### Subgroup analyses of secondary outcomes

  **Secondary outcomes**   **Num of studies**   **HR((95% CI)**     ***P***   ***P~h~***
  ------------------------ -------------------- ------------------- --------- ------------
  PFS                      3                    1.31 (0.76--2.27)   0.33      0.005
  CSS                      1                    1.44 (1.04--1.99)   0.03      \-

PFS, progression-free survival; CSS, cancer-specific survival; *P*h, *P*-values for heterogeneity from *Q* test.

Cancer-specific survival {#s3_4}
------------------------

Only one study comprising 298 patients reported hazard ratios for CSS. Overall, SII over the cutoff was associated with a hazard ratio for worse CSS outcome. The HR for CSS was 1.44 (95% CI = 1.04--1.99, *P =* 0.03, Table [3](#T3){ref-type="table"}).

DISCUSSION {#s4}
==========

Many recent studies \[[@R8], [@R9], [@R16], [@R20]--[@R22], [@R24], [@R25], [@R27], [@R28]\] have suggested that an elevated SII is associated with poor overall survival or progression free survival of patients with cancers. While several studies \[[@R18], [@R19], [@R23], [@R26]\] show that SII is not significantly associated with overall survival. Thus the results of published studies are inconsistent. Here we undertook a meta-analysis of 16 studies including 4875 patients with solid tumors to assess whether SII was associated with prognosis of solid tumor. Overall, we found a significant association between elevated SII and poor survival. Consistent results were observed in various cancer subgroups, including hepatocellular carcinoma, gastrointestinal tract cancers, urinary cancers, small cell lung cancer and acral melanoma. Differences in HRs were observed between cancer sites and may be the result of inflammation playing different roles in different types of cancer. In addition, a trend for the association of high SII with worse OS was greater for metastatic/mixed cases than that in the nonmetastatic diseases. This may reflect either increased tumor burden or a long term inflammatory process \[[@R29]\]. The cutoff of SII in included studies didn't reach a standard point, and the method to determine the cutoffs is not described in many studies. Cutoffs of SII varied among the included studies, however, meta-regression analysis showed that there was no association between SII cutoff and reported HR for OS. Thus, it was unlikely to influence our results. However, the cutoff value must be established in one cohort of patients and tested in another and the number of patients in each group needs to be considered in the statistical analysis \[[@R30]\].

Several studies may give explanations for the prognostic values of SII in tumors: Neutrophils activate endothelium and parenchymal cells via soluble factors secretion, enhancing circulating tumor cell adhesion in distant sites \[[@R31]--[@R33]\]. In addition, clinical studies have suggested that increased numbers of circulating neutrophils are associated with adverse prognosis in patients with cancers \[[@R34]\]. The effects of platelets on metastatic have been attributed to their ability to promote adhesion or to their capacity to prevent cell death. This is owing to the physical shield around tumor cells they formed \[[@R35]\]. Therefore, platelets may contribute to progression and metastasis of cancers. Lymphocytes play a crucial role in cancer immune surveillance and defense via cytotoxic cell death and inhibition tumor cell proliferation and migration \[[@R4]\]. Thus, due to high levels of neutrophils and platelets while low level of lymphocytes, a higher SII usually indicates a stronger inflammatory and a weaker immune response in patients. It may be associated with invasion and metastasis of tumor cells and hence lead to poor survival.

Some limitations of our meta-analysis existed. Firstly, the number of published studies included was not large enough for subgroup analysis. Secondly, only studies reporting HR and 95% confidence interval was included in our meta-analysis. Thus, further bias was potentially introduced. In addition, one study only reported univariate hazard ratio, which could introduce a bias toward overestimation of the prognostic role of SII. Finally, lymphocyte, neutrophil and platelet counts are commonly affected by the existence of infection, chemotherapy and other related factors and studies included in this meta-analysis did not strictly control these confounding factors. However, most cases included in the studies are patients who are going to have surgery and chemotherapy, which indicates that most cases were under non-infectious state when the peripheral blood for calculating SII was gathered. But we should admit that there are so many other factors such as the existence of dehydration, which is common but hard to control that affect the SII result.

In conclusion, our meta-analysis suggests elevated SII indicated poor prognosis and SII may serve as a cost-effective prognostic biomarker. Subgroup analyses by cancer sites identified consistent results in various solid tumors, including hepatocellular carcinoma, gastrointestinal tract cancers, urinary cancers, small cell lung cancer and acral melanoma. The clinical significance of SII as a prognostic indicator must be further validated.

SUPPLEMENTARY MATERIALS FIGURE {#s5}
==============================

**CONFLICTS OF INTEREST**

The authors declare that there are no conflicts of interest regarding the publication of this paper.
